US 11,654,200 B2
Compositions and methods for delivery of RNA
Amit Khandhar, Seattle, WA (US); Steven Reed, Seattle, WA (US); Malcolm Duthie, Seattle, WA (US); Jesse Erasmus, Seattle, WA (US); Darrick Carter, Seattle, WA (US); and Bryan J. Berube, Seattle, WA (US)
Assigned to HDT Bio Corp., Seattle, WA (US)
Filed by HDT Bio Corp., Seattle, WA (US)
Filed on Dec. 5, 2022, as Appl. No. 18/61,725.
Application 18/061,725 is a continuation of application No. 17/839,574, filed on Jun. 14, 2022.
Application 17/839,574 is a continuation of application No. 17/702,730, filed on Mar. 23, 2022, granted, now 11,433,142, issued on Sep. 6, 2022.
Application 17/702,730 is a continuation of application No. 17/523,457, filed on Nov. 10, 2021, granted, now 11,318,213, issued on May 3, 2022.
Application 17/523,457 is a continuation of application No. PCT/US2021/019103, filed on Feb. 22, 2021.
Claims priority of provisional application 63/054,754, filed on Jul. 21, 2020.
Claims priority of provisional application 62/993,307, filed on Mar. 23, 2020.
Prior Publication US 2023/0107137 A1, Apr. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/69 (2017.01); A61K 9/107 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 47/02 (2006.01); A61K 47/44 (2017.01); A61P 31/14 (2006.01); A61K 9/127 (2006.01); A61K 39/215 (2006.01); C12N 15/86 (2006.01); A61K 9/51 (2006.01); A61K 31/713 (2006.01); A61K 39/39 (2006.01); A61K 49/18 (2006.01); C07K 14/165 (2006.01); C12N 15/88 (2006.01); B82Y 5/00 (2011.01); B82Y 25/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01); A61K 39/00 (2006.01); A61K 47/54 (2017.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01)
CPC A61K 47/6907 (2017.08) [A61K 9/1075 (2013.01); A61K 9/127 (2013.01); A61K 9/5115 (2013.01); A61K 9/5123 (2013.01); A61K 31/711 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 39/215 (2013.01); A61K 39/39 (2013.01); A61K 47/02 (2013.01); A61K 47/44 (2013.01); A61K 47/6911 (2017.08); A61K 47/6923 (2017.08); A61K 49/183 (2013.01); A61K 49/1833 (2013.01); A61P 31/14 (2018.01); C07K 14/165 (2013.01); C12N 15/86 (2013.01); C12N 15/88 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/547 (2017.08); A61K 2039/55555 (2013.01); B82Y 5/00 (2013.01); B82Y 25/00 (2013.01); B82Y 30/00 (2013.01); B82Y 40/00 (2013.01); C12N 2770/36143 (2013.01)] 43 Claims
OG exemplary drawing
 
1. A method for delivering nucleic acids for generating an immune response with enhanced safety, comprising administering to a subject: a composition, wherein the composition comprises:
lipid nanoparticles, wherein the lipid nanoparticles are characterized as having a z-average diameter particle size measurement of about 20 nm to about 60 nm when measured using dynamic light scattering, and wherein the lipid nanoparticles comprise a hydrophobic core comprising lipids present in liquid phase at 25 degrees Celsius; and
nucleic acids,
wherein the nucleic acids are complexed to the lipid nanoparticles to form nucleic acid-lipid nanoparticle complexes, and wherein the administering of the composition provides for enhanced safety characterized by a reduction in systemic adverse reactions compared to administration of a composition wherein the nucleic acids are encapsulated in the lipid nanoparticles.